EpiVax CEO/CSO Annie De Groot hosted a talk for the FDA Office of Tissues and Advanced Therapies (OTAT) group on February 11, 2021. Annie presented the latest on EpiVax’s iVAX Toolkit in her talk “Epitope Selection for Cancer Vaccines”. JanusMatrix, our tool for assessing cross-conservation of epitope content with the human genome, features prominently as it allows cancer researchers to predict likelihood of immune tolerance for candidate molecules.